Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorROMANI, Serena
dc.contributor.authorFRESSE, Audrey
dc.contributor.authorPARASSOL-GIRARD, Nadege
dc.contributor.authorGERARD, Alexandre
dc.contributor.authorLEVRAUT, Mathieu
dc.contributor.authorYAMANI, Samir
dc.contributor.authorVAN OBBERGHEN, Elise
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.contributor.authorROCHER, Fanny
dc.contributor.authorVIARD, Delphine
dc.contributor.authorDRICI, Milou-Daniel
dc.date.accessioned2022-02-16T15:23:21Z
dc.date.available2022-02-16T15:23:21Z
dc.date.issued2022-01-06
dc.identifier.issn1472-8206 (Electronic) 0767-3981 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124747
dc.description.abstractEnFollowing minor changes of excipients of Levothyrox®, the French Pharmacovigilance Database was overwhelmed by patients' spontaneous reports of adverse drug reactions associated with the new formula. After noticing that most of these reports differed from those related to other drugs, we aimed to characterize their features and compared them with spontaneous reports associated with other chronic treatments as comparators. We randomly sampled patient reports associated with either Levothyrox® new formula (n=200) or with comparator drugs (n=200) from March 2017 till March 2018 from the national pharmacovigilance database. We evaluated the number of incriminated drugs and adverse drug reactions per report, and verified whether they were "expected" or not according to the Summary of Product Characteristics. Levothyrox® associated reports included, on average, more adverse drug reactions (8±4) than comparators (2±2, p<0.01), and mentioned mostly 1 drug (98.5% of reports) whereas comparators mentioned 2 at least (p<0.001). The quantitative distribution of adverse drug reactions per report differed quite significantly, appearing almost Gaussian for Levothyrox® whereas Poisson-like for comparators (p<0.0001). Age did not differ significantly in the two groups (54.2 versus 49.7, p>0.05), but female predominated in Levothyrox® group (94.5%) as compared with comparators (60.8%, p<0.001). A mere third of the Levothyrox® associated adverse drug reactions were deemed "expected", versus two-third for comparators (p<0.001). The pattern of spontaneous reports associated with Levothyrox®, whether fueled by media or influenced by social networks, appears atypical, as compared with that of comparators. Such reports, by their abundance may impair the automatic detection of relevant concomitant signals.
dc.language.isoENen_US
dc.subject.enAdverse drug reaction
dc.subject.enLevothyrox®
dc.subject.enMedia coverage
dc.subject.enMedia inference
dc.subject.enSpontaneous reporting
dc.title.enSpontaneous reporting of adverse-drug reactions as an outlet for patient dismay? The case of Levothyrox(R) change of excipients
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/fcp.12755en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34989440en_US
bordeaux.journalFundamental and Clinical Pharmacologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03577347
hal.version1
hal.date.transferred2022-02-16T15:23:23Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Fundamental%20and%20Clinical%20Pharmacology&amp;rft.date=2022-01-06&amp;rft.eissn=1472-8206%20(Electronic)%200767-3981%20(Linking)&amp;rft.issn=1472-8206%20(Electronic)%200767-3981%20(Linking)&amp;rft.au=ROMANI,%20Serena&amp;FRESSE,%20Audrey&amp;PARASSOL-GIRARD,%20Nadege&amp;GERARD,%20Alexandre&amp;LEVRAUT,%20Mathieu&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée